{"status": "Ok", "redirect_url": "https://www.prnewswire.com//news-releases/regeneron-pharmaceuticals-inc-regn-faces-securities-class-action-amid-disclosures-about-key-trials-protocol-and-ultimate-failure---hbss-302840222.html", "message": "News view counter 861684 successfully enlarged"}